Clinical effects of Cangepingchuanjiaonang in the treatment of non-small cell lung cancer with chronic obstructive pulmonary disease in elderly patients

doi:10.3877/cma.j.issn.1674-6902.2017.05.009

Abstract

Abstract:

Objective

To investigate the clinical effects of cangepingchuanjiaonang in the treatment of non-small cell lung cancer (NSCLC) with Chronic obstructive pulmonary disease (COPD) in elderly patients.

Methods

114 elderly patients from Jan 2014 to Jan 2016 with advanced NSCLC with COPD in our hospital were randomly divided observation group and control group. The patients were treated with regular treatment, included oxygen, dilated bronchi and GP chemotherapy. The observation group was given cangepingchuanjiaonang on the base of control group. After treatment, the curative effects were evaluated. Before and after the treatment, the levels of DLCO, FEV₁, FEV₁/FVC, CD3⁺ , CD4⁺ , CD8⁺ , IgG, IgA and IgM were detected in the two groups. Then the toxicity of the two groups was compared.

Results

The total effective rate was 84.2% in the observation group, significantly higher than the control group (P<0.05). After the treatment, the levels of DLCO, FEV₁, FEV₁/FVC, CD3⁺ , CD4⁺ , CD8⁺ , IgG, IgA and IgM were significantly higher in the observation group than which in the control group (P<0.05). During the treatment, there were no serious toxicity in the two groups and the rates of toxicity were significantly lower in the observation group than which in the control group (P<0.05).

Conclusion

Cangepingchuanjiaonang in the treatment of NSCLC with COPD in elderly patients has a good effect and worth to the next research.

Key words: Non-small cell lung cancer, Chronic obstructive pulmonary disease, Cangepingchuanjiaonang

Long Gao, Qilong Zhang, Hui Tian. Clinical effects of Cangepingchuanjiaonang in the treatment of non-small cell lung cancer with chronic obstructive pulmonary disease in elderly patients[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(05): 549-553.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.05.009

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I05/549

Figures/Tables 4

References 22

1	廖晨，余祖滨，张萍，等. 慢性阻塞性肺疾病合并肺癌122例临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(1): 30-34.
2	任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
3	Liao C, Yu ZB, Meng G, et al. Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease[J]. Cancer, 2015, 121 Suppl 17: 3122-3129.
4	Senbaklavaci O. Lobar lung resection in elderly patients with non-small cell lung carcinoma: impact of chronic obstructive pulmonary disease on surgical outcome[J]. Int Surg, 2014, 99(4): 319-324.
5	Deepak JA, Ng X, Feliciano J, et al. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lungcancer and？chronic obstructive pulmonary disease[J]. Ann Am Thorac Soc, 2015, 12(5): 742-751.
6	Qiang G, Liang C, Xiao F, et al. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer[J]. Int J Chron Obstruct Pulmon Dis, 2015, 11: 43-49.
7	Stefanelli F, Meoli I, Cobuccio R, et al. High-intensity training and cardiopulmonary exercise testing in patients with chronic obstructive pulmonary disease and non-small-cell lung cancer undergoing lobectomy[J]. Eur J Cardiothorac Surg, 2013, 44(4): e260-265.
8	赵艳，万毅新，陶红艳. 慢性炎症与慢性阻塞性肺疾病和肺癌进展的研究[J]. 临床肺科杂志，2013, 13(1): 108-109.
9	张毅，蔡志刚，徐臻，等. 参蛤平喘汤对慢性阻塞性肺疾病缓解期干预研究[J]. 辽宁中医药大学学报，2015, 17(1): 196-198.
10	Zhao DY, Qu HJ, Guo JM, et al. Protective Effects of Myrtol Standardized Against Radiation-Induced Lung Injury[J]. Cell Physiol Biochem, 2016, 38(2): 619-634.
11	中华人民共和国卫生部医政司. 中国常见恶性肿瘤诊治规范[M]. 第2版. 北京：北京医科大学中国协和医科大学联合出版社，1996: 16.
12	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志，2013, 36(4): 255.
13	Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2014, 9: 1618-1624.
14	Jahangeer S, Forde P, Soden D, et al. Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours[J]. Cancer Treat Rev, 2013, 39(8): 862-871.
15	Jiang XD, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer[J]. Clin Transl Oncol, 2012, 14(6): 437-443.
16	Bao Y, Peng F, Zhou QC, et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer[J]. Radiother Oncol, 2015, 114(2): 161-166.
17	Kuo CH, Wu CY, Lee KY, et al. Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter[J]. COPD, 2014, 11(4): 407-413.
18	Jeon JH, Kang CH, Kim HS, et al. Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: a propensity score-matched analysis[J]. Eur J Cardiothorac Surg, 2014, 45(4): 640-645.
19	Yamanashi K, Marumo S, Shoji T, et al. The relationship between perioperative administration of inhaled corticosteroid and postoperative respiratory complications after pulmonary resection for non-small-cell lung cancer in patients withchronic obstructive pulmonary disease[J]. Gen Thorac Cardiovasc Surg, 2015, 63(12): 652-659.
20	马恒宾，佟倜，王青光，等. 慢性阻塞性肺疾病合并肺癌的研究进展[J]. 中国老年学杂志，2013, 33 (4): 1716- 1719.
21	星海霞，姚惠青，赵永祥. 参蛤河车胶囊联合布地奈德福莫特罗治疗慢性阻塞性肺疾病缓解期的临床观察[J]. 陕西中医，2016, 37(9): 1127-1129.
22	马宝兰，秦緖花，史载祥，等. 西洋参临床药理研究进展[J]. 江西中医学院学报，2013, 25(5): 88-92.

组　别	例数	CR	PR	SD	PD	总有效率
观察组	57	12	36	3	6	48(84.2)
对照组	57	8	23	19	7	31(54.3)
χ²值	－	－	－	－	－	4.012
P值	－	－	－	－	－	0.039

组　别	例数	CR	PR	SD	PD	总有效率
观察组	57	12	36	3	6	48(84.2)
对照组	57	8	23	19	7	31(54.3)
χ²值	－	－	－	－	－	4.012
P值	－	－	－	－	－	0.039

组　别	治疗前/后	例数	DLCO(ml·min^－1·mmHg^－1)	FEV₁(L)	FEV₁/FVC(%)
观察组	治疗前	57	60.32±9.28	61.34±9.11	57.87±11.28
?	治疗后	57	72.27±10.89	71.15±11.22	70.25±13.09
对照组	治疗前	57	60.66±9.39	60.95±9.14	58.02±11.38
?	治疗后	57	66.33±10.33	66.23±10.34	63.31±12.21
t值	?	?	4.382	4.429	4.724
?	?	?	3.981	4.003	4.221
?	?	?	2.761	2.434	2.927
P值	?	?	<0.001	<0.001	<0.001
?	?	?	<0.001	<0.001	<0.001
?	?	?	0.012	0.016	0.004

组　别	治疗前/后	例数	DLCO(ml·min^－1·mmHg^－1)	FEV₁(L)	FEV₁/FVC(%)
观察组	治疗前	57	60.32±9.28	61.34±9.11	57.87±11.28
?	治疗后	57	72.27±10.89	71.15±11.22	70.25±13.09
对照组	治疗前	57	60.66±9.39	60.95±9.14	58.02±11.38
?	治疗后	57	66.33±10.33	66.23±10.34	63.31±12.21
t值	?	?	4.382	4.429	4.724
?	?	?	3.981	4.003	4.221
?	?	?	2.761	2.434	2.927
P值	?	?	<0.001	<0.001	<0.001
?	?	?	<0.001	<0.001	<0.001
?	?	?	0.012	0.016	0.004

组　别	治疗前/后	例数	免疫球蛋白(g/L)			T淋巴细胞亚群(%)
组　别	治疗前/后	例数	IgG	IgA	IgM	CD3^＋	CD4^＋	CD8^＋
观察组	治疗前	61	7.31±0.85	1.24±0.12	1.23±0.12	40.23±7.17	33.56±4.84	26.56±3.15
?	治疗后	61	13.31±1.86	2.89±0.27	2.27±0.31	64.66±8.34	45.45±6.34	33.73±4.87
对照组	治疗前	61	7.34±0.87	1.26±0.16	1.35±0.13	41.35±7.34	32.67±4.67	26.45±3.35
?	治疗后	61	9.54±1.17	1.76±0.15	1.86±0.34	58.13±7.54	37.23±5.45	31.17±4.35
t值	?	?	24.319	34.651	9.221	9.110	8.342	5.562
?	?	?	21.581	29.217	7.893	6.278	6.128	4.147
?	?	?	12.953	27.621	6.728	4.385	7.423	2.960
P值	?	?	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
?	?	?	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
?	?	?	<0.001	<0.001	<0.001	<0.001	<0.001	0.004

Please choose a citation manager

Content to export